In fact, SGLT2 inhibitors are expected and being studied whether to ameliorate Alzheimer’s disease and autosomal dominant polycystic kidney disease (ADPKD) via improving their autophagy deficiencies, in which diseases the AMPK/mTOR pathway influences their progression. The gene discussed is MTOR; the disease is autosomal dominant polycystic kidney disease.